Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

Mult Scler. 2024 Mar;30(3):443-447. doi: 10.1177/13524585231207761. Epub 2023 Nov 9.

Abstract

Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear.

Methods: Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination.

Results: Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant.

Conclusion: Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients.

Keywords: COVID-19; S1P modulators; antibodies; immunization; omicron.

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19*
  • Fingolimod Hydrochloride
  • Humans
  • Multiple Sclerosis*
  • Prospective Studies
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines
  • Fingolimod Hydrochloride
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants